相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
Siddhartha Yadav et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
The impact of coding germline variants on contralateral breast cancer risk and survival
Anna Morra et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2023)
Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk
Rick A. C. M. Boonen et al.
CANCER RESEARCH (2022)
Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant
Yael Laitman et al.
FAMILIAL CANCER (2022)
Diversity in cancer genomics research is a matter of equity and scientific discovery
Tuya Pal
GENETICS IN MEDICINE (2022)
Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank
Louise Wang et al.
GENETICS IN MEDICINE (2022)
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants A Comparative Modeling Analysis
Kathryn P. Lowry et al.
JAMA ONCOLOGY (2022)
Breast cancer risks associated with missense variants in breast cancer susceptibility genes
Leila Dorling et al.
GENOME MEDICINE (2022)
Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK)
Lucy Loong et al.
GENETICS IN MEDICINE (2022)
An updated counseling framework for moderate-penetrance colorectal cancer susceptibility genes
Kelsey E. Breen et al.
GENETICS IN MEDICINE (2022)
Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2
Brittany L. Bychkovsky et al.
JAMA ONCOLOGY (2022)
Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes
Grace Wei et al.
BREAST CANCER RESEARCH (2022)
CHEK2 mutations and papillary thyroid cancer: correlation or coincidence?
Kortbeek Koen et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2022)
Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue
Valeriya I. Ni et al.
FAMILIAL CANCER (2021)
Skin cancer risk in CHEK2 mutation carriers
A. N. Bui et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants
Petra Vukovic et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Does the law require reinterpretation and return of revised genomic results?
Ellen Wright Clayton et al.
GENETICS IN MEDICINE (2021)
Germline Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group
He Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
A Population-Based Study of Genes Previously Implicated in Breast Cancer
Chunling Hu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women
Leila Dorling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma
Danuta Gasior-Perczak et al.
CANCERS (2021)
Taking an antiracist posture in scientific publications in human genetics and genomics
Kyle B. Brothers et al.
GENETICS IN MEDICINE (2021)
The context-specific role of germline pathogenicity in tumorigenesis
Preethi Srinivasan et al.
NATURE GENETICS (2021)
Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients
Kristoffer von Stedingk et al.
SCIENTIFIC REPORTS (2021)
Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk
Burcu F. Darst et al.
EUROPEAN UROLOGY (2021)
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)
David T. Miller et al.
GENETICS IN MEDICINE (2021)
Companion Tumor Sequencing to Assess the Clinical Significance of Germline Sequencing in Children With Cancer
Tinaye Mutetwa et al.
JAMA NETWORK OPEN (2021)
Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score
Chi Gao et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study
Jung Kim et al.
JNCI CANCER SPECTRUM (2021)
CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants
Tim Carver et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2021)
Is there a duty to reinterpret genetic data? The ethical dimensions
Paul S. Appelbaum et al.
GENETICS IN MEDICINE (2020)
High risk of breast cancer in women with biallelic pathogenic variants in CHEK2
Irene Rainville et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer
Anne S. Reiner et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer
Allison W. Kurian et al.
JAMA ONCOLOGY (2020)
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers
Deborah Cragun et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing
Erin G. Sutcliffe et al.
CANCER GENETICS (2020)
Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer
Tiffiney R. Hartman et al.
SCIENTIFIC REPORTS (2020)
Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland
Dominika Wokolorczyk et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Expectations of Surveillance for Non-BRCA Gene Mutation Carriers at Increased Risk for Breast Cancer
Rachel Caskey et al.
JOURNAL OF SURGICAL RESEARCH (2020)
The role of polygenic risk and susceptibility genes in breast cancer over the course of life
Nina Mars et al.
NATURE COMMUNICATIONS (2020)
Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype
Tamar Paperna et al.
JOURNAL OF MEDICAL GENETICS (2020)
DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes (vol 21, pg 683, 2018)
Marcy E. Richardson et al.
GENETICS IN MEDICINE (2019)
Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel
Daniel A. Leongamornlert et al.
EUROPEAN UROLOGY (2019)
Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system
Angeliki Delimitsou et al.
HUMAN MUTATION (2019)
Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma
O. Obazee et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors
Saud H. AlDubayan et al.
JAMA ONCOLOGY (2019)
Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group
D. Mandelker et al.
ANNALS OF ONCOLOGY (2019)
Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG)
Joshua L. Deignan et al.
GENETICS IN MEDICINE (2019)
Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer
Petra Kleiblova et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report
Amanda B. Spurdle et al.
JOURNAL OF MEDICAL GENETICS (2019)
Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer
Christos Petridis et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2019)
The All of Us Research Program
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing
Hsiao-Mei Lu et al.
JAMA ONCOLOGY (2019)
Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics
Daniele Carrieri et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2019)
The illusion of polygenic disease risk prediction
Nicholas J. Wald et al.
GENETICS IN MEDICINE (2019)
Patient re-contact after revision of genomic test results: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG)
Karen L. David et al.
GENETICS IN MEDICINE (2019)
Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy
Piera Rizzolo et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing
Veda N. Giri et al.
PROSTATE (2019)
The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers
Diana Mandelker et al.
JNCI CANCER SPECTRUM (2019)
Integrative data fusion for comprehensive assessment of a novel CHEK2 variant using combined genomics, imaging, and functional-structural assessments via protein informatics
Stephanie L. Hines et al.
MOLECULAR OMICS (2019)
Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history
Kari G. Chaffee et al.
GENETICS IN MEDICINE (2018)
Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk
Allison H. West et al.
FAMILIAL CANCER (2018)
Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer
Zhaoming Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women
Ranjit Manchanda et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
Hermela Shimelis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
Sebastian M. Waszak et al.
LANCET ONCOLOGY (2018)
Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis
Mingming Liang et al.
MOLECULAR DIAGNOSIS & THERAPY (2018)
Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer
Pedro Isaacsson Velho et al.
PROSTATE (2018)
A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer
Yishuo Wu et al.
PROSTATE (2018)
Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women
Ranjit Manchanda et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
Hermela Shimelis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma
Maria I. Carlo et al.
JAMA ONCOLOGY (2018)
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results
Mary Pritzlaff et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Genetic modifiers of CHEK2*1100delC-associated breast cancer risk
Taru A. Muranen et al.
GENETICS IN MEDICINE (2017)
Colorectal cancer risk associated with the CHEK2 1100delC variant
Bryson W. Katona et al.
EUROPEAN JOURNAL OF CANCER (2017)
Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls
Jenna Lilyquist et al.
GYNECOLOGIC ONCOLOGY (2017)
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
Paz Polak et al.
NATURE GENETICS (2017)
The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
Marcin R. Lener et al.
CANCER RESEARCH AND TREATMENT (2017)
CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
Sanna Hallamies et al.
BMC CANCER (2017)
A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes
Saundra S. Buys et al.
CANCER (2017)
Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients
Chunling Hu et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
Wendy Chang et al.
CLINICAL CANCER RESEARCH (2016)
Recontact in clinical practice: a survey of clinical genetics services in the United Kingdom
Daniele Carrieri et al.
GENETICS IN MEDICINE (2016)
Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?
Marcin R. Lener et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Age- and Tumor Subtype Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers
Marjanka K. Schmidt et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Multigene Panels to Evaluate Hereditary Cancer Risk: Reckless or Relevant?
Michael J. Hall et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2☆1100delC Heterozygotes Estimated From the Copenhagen General Population Study
Charlotte Naslund-Koch et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing
Judith Balmana et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Melissa C. Southey et al.
JOURNAL OF MEDICAL GENETICS (2016)
Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort
Kari L. Ring et al.
MODERN PATHOLOGY (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression
Vito Alessandro Lasorsa et al.
ONCOTARGET (2016)
Implementation of next generation sequencing into pediatric hematologyoncology practice: moving beyond actionable alterations
Jennifer A. Oberg et al.
GENOME MEDICINE (2016)
Patient survival and tumor characteristics associated with CHEK2:p.I157T-findings from the Breast Cancer Association Consortium
Taru A. Muranen et al.
BREAST CANCER RESEARCH (2016)
Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
Maarten P. G. Massink et al.
BMC CANCER (2015)
Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer
Yin Liu et al.
BMC CANCER (2015)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
CHEK2 mutations and the risk of papillary thyroid cancer
Monika Siolek et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Rajen J. Mody et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population
Marta Kaczmarek-Rys et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2015)
Survival from breast cancer in patients with CHEK2 mutations
T. Huzarski et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers
Werner Pfeifer et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface
A. J. Lee et al.
BRITISH JOURNAL OF CANCER (2014)
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
M. Kriege et al.
BRITISH JOURNAL OF CANCER (2014)
CHEK2 star 1100delC homozygosity in the Netherlands-prevalence and risk of breast and lung cancer
Petra E. A. Huijts et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2014)
Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes
Thereasa A. Rich et al.
FAMILIAL CANCER (2014)
Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence
Xiangyu Ma et al.
GUT (2014)
Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele
Evgeny N. Suspitsin et al.
MEDICAL ONCOLOGY (2014)
The risk of gastric cancer in carriers of CHEK2 mutations
Urszula Teodorczyk et al.
FAMILIAL CANCER (2013)
Technical report: ethical and policy issues in genetic testing and screening of children
Laine Friedman Ross et al.
GENETICS IN MEDICINE (2013)
The CHEK2 I157T Variant and Colorectal Cancer Susceptibility: A Systematic Review and Meta-analysis
Chuan Liu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer
Pawel Domagala et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
High-risk consumers' perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis
Gwendolyn P. Quinn et al.
GENETICS IN MEDICINE (2012)
A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations
Hanna Janiszewska et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer
Maren Weischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis
Maren Weischer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients
S. G. Angelova et al.
NEOPLASMA (2012)
Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility
He-ping Xiang et al.
EUROPEAN JOURNAL OF CANCER (2011)
CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women
Muriel A. Adank et al.
JOURNAL OF MEDICAL GENETICS (2011)
Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma
O. Havranek et al.
NEOPLASMA (2011)
Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort
N. M. McInerney et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
CHEK2 mutations and HNPCC-related colorectal cancer
Janina Suchy et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention
C. Cybulski et al.
CLINICAL GENETICS (2009)
CHEK2 I157T and Endometrial Cancer
Darina V. Konstantinova et al.
DNA AND CELL BIOLOGY (2009)
The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population
Zdenek Kleibl et al.
EUROPEAN JOURNAL OF CANCER (2009)
Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations
Bella Kaufman et al.
FAMILIAL CANCER (2009)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study
L. Mellemkjaer et al.
BRITISH JOURNAL OF CANCER (2008)
Frequency of the CHEK2 1100delC mutation among women with breast cancer:: An international study
Shiyu Zhang et al.
CANCER RESEARCH (2008)
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers
Cezary Cybulski et al.
CARCINOGENESIS (2008)
CHEK2* 1100delC genotyping for clinical assessment of breast cancer risk:: Meta-analyses of 26,000 patient cases and 27,000 controls
Maren Weischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Is CHEK2 a cause of the Li-Fraumeni syndrome?
D. G. Evans et al.
JOURNAL OF MEDICAL GENETICS (2008)
Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers:: case-control study
Paul Brennan et al.
HUMAN MOLECULAR GENETICS (2007)
Breast cancer in patients carrying a germ-line CHEK2 mutation:: Outcome after breast conserving surgery and adjuvant radiotherapy
Andreas Meyer et al.
RADIOTHERAPY AND ONCOLOGY (2007)
Germline CHEK2 mutations and colorectal cancer risk:: different effects of a missense and truncating mutations?
Cezary Cybulski et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2007)
Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study
Annegien Broeks et al.
BREAST CANCER RESEARCH (2007)
Increased risk of breast cancer associated with CHEK2*1100delC
Maren Weischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation
Marjanka K. Schmidt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Low frequency of CHEK2 mutations in familial pancreatic cancer
Detlef K. Bartsch et al.
FAMILIAL CANCER (2006)
Cancer genetic testing and assisted reproduction
Kenneth Offit et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pathology of breast cancer in women with constitutional CHEK2 mutations
T Huzarski et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients
O Kilpivaara et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Novel founder CHEK2 mutation is associated with increased prostate cancer risk
C Cybulski et al.
CANCER RESEARCH (2004)
CHEK2 1100delC is not a risk factor for male breast cancer population
K Syrjäkoski et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant
GH de Bock et al.
JOURNAL OF MEDICAL GENETICS (2004)
CHEK2 is a multiorgan cancer susceptibility gene
C Cybulski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers
A Broeks et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype
H Meijers-Heijboer et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Mutations in CHEK2 associated with prostate cancer risk
XY Dong et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome
N Sodha et al.
HUMAN MUTATION (2002)
Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations
H Meijers-Heijboer et al.
NATURE GENETICS (2002)
To the editor: Mutations of Chk2 in primary hematopoietic neoplasms
A Hangaishi et al.
BLOOD (2002)
分享论文
